A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Status:
Active, not recruiting
Trial end date:
2022-08-10
Target enrollment:
Participant gender:
Summary
A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of
lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic
ALK positive non small cell lung cancer patients in China